Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes
| datacite.rights | http://purl.org/coar/access_right/c_abf2 | |
| dc.contributor.author | Rico-Fontalvo, Jorge | |
| dc.contributor.author | Daza-Arnedo, Rodrigo | |
| dc.contributor.author | Rodríguez-Yánez, Tomas | |
| dc.contributor.author | Soler, María J. | |
| dc.date.accessioned | 2024-12-16T14:01:38Z | |
| dc.date.available | 2024-12-16T14:01:38Z | |
| dc.date.issued | 2024 | |
| dc.description.abstract | Dear Editor, we would like to congratulate Dr. Perkovic and colleagues demonstrating that semaglutide reduced by 24% the risk of kidney outcomes and death from cardiovascular causes in persons with type 2 diabetes (T2D) and chronic kidney disease (CKD)1. In SUSTAIN 6, semaglutide showed renal benefits mainly in terms of albuminuria reduction, interestingly the metabolic effects (blood sugar control and body weight) were higher in the 1 mg dose as compared to 0.5 mg2. In concordance, in the SUSTAIN FORTE, the 2 mg weekly dose was also better in metabolic control3, indicating that the effect is in part dose-dependent. In addition, when studying kidney function Shaman et al. found that 1 mg of semaglutide has a higher effect in reducing albuminuria and delaying glomerular filtration rate progression as compared to liraglutide 1.8 mgs/day and low semaglutide dose 0.5 mgs/weekly4. | eng |
| dc.format.mimetype | ||
| dc.identifier.doi | https://dx.doi.org/10.24875/NEFRO.24000031 | |
| dc.identifier.issn | 24449032 (Electrónico) | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/16064 | |
| dc.identifier.url | https://www.nefrologialatinoamericana.com/files/es/nefro_24_21_3_096-097.pdf | |
| dc.language.iso | eng | |
| dc.publisher | Sociedad Latinoamericana de Nefrología e Hipertensión | spa |
| dc.rights | Attribution-NonCommercial-NoDerivs 3.0 United States | eng |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/us/ | |
| dc.source | Nefrología Latinoamericana | spa |
| dc.source | Nefro Latinoam. | eng |
| dc.source | Vol. 21, No. 3 (2024) | spa |
| dc.subject.keywords | Type 2 diabetes | eng |
| dc.subject.keywords | Chronic kidney disease | eng |
| dc.title | Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes | eng |
| dc.title.translated | Efecto de semaglutide sobre la enfermedad renal crónica en pacientes con diabetes mellitus tipo 2 | spa |
| dc.type.driver | info:eu-repo/semantics/article | |
| dc.type.spa | Artículo científico | |
| dcterms.references | Perkovic V, Tuttle K, Rossing P, Mahaffey K, Man J, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients wtih Type 2 diabetes. N Engl J Med. 2024;391:109-21. | eng |
| dcterms.references | Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-44. | eng |
| dcterms.references | Frías JP, Auerbach P, Bajaj HS, Fukushima Y, Lingvay I, Macura S, et al. Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol. 2021;9:563-74. | eng |
| dcterms.references | Shaman AM, Bain SC, Bakris GL, Buse JB, Idorn T, Mahaffey KW, et al. Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and leader. Circulation. 2022;145:575-85. | eng |
| dcterms.references | Ryan DH, Lingvay I, Deanfield J, Kahn SE, Barros E, Burguera B, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024;30:2049-57. | eng |
| oaire.version | info:eu-repo/semantics/publishedVersion |